Shots:
- Boehringer Ingelheim and CDR-Life signed a global licensing deal to develop CDR111, a trispecific M-gager T-cell engager targeting and depleting B cells to help reset the immune system in autoimmune diseases
- As per the deal, CDR-Life could receive up to CHF 456M (~$570M), including CHF 38M (~$ 48M) upfront and near-term payments, plus tiered royalties
- The deal extends the companies’ prior collaboration on an investigational antibody fragment for geographic atrophy, currently in Boehringer’s Verdant P-II trial
Ref: CDR-Life | Image: Boehringer Ingelheim & CDR-Life | Press Release
Related News:- Boehringer Ingelheim Licenses an Autoimmune Disease Therapy from Kyowa Kirin for ~$744.4M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
